热景生物公告称，公司于11月11日召开董事会，审议通过以集中竞价交易方式回购股份方案。回购资金 1亿-2亿元，来源为自有资金，价格不超244元/股，拟回购409,837-819,672股，占总股本0.44%-0.88%， 用于员工持股计划或股权激励。回购期限自董事会审议通过起12个月内。此外，控股股东等相关人员在 决议前6个月内有减持，回购期间暂无明确增减持计划。本次回购存在价格、资金、重大事项等风险。 ...

Core Viewpoint - The company plans to repurchase its A-shares using its own funds through a centralized bidding method, with a total repurchase amount between RMB 40 million and RMB 80 million, aimed at employee stock ownership plans or equity incentives [2][3][10]. Summary by Sections Repurchase Plan Details - The repurchase amount will not be less than RMB 40 million and not exceed RMB 80 million [2]. - The repurchase price will not exceed RMB 25 per share, which is 150% of the average trading price over the last 30 trading days prior to the board's decision [2][12]. - The repurchase will be conducted through a centralized bidding method [3][7]. - The repurchase period is set for 12 months from the board's approval date [3][8]. Purpose and Use of Repurchased Shares - The repurchase aims to enhance investor confidence and align the interests of shareholders and the management team, with shares intended for employee stock ownership plans or equity incentives [6][10]. - The repurchased shares must be transferred within three years for the stated purpose, or they will be canceled [10][12]. Financial Impact and Conditions - The total assets of the company as of September 30, 2025, are RMB 4.873 billion, with net assets of RMB 2.093 billion and revenue of RMB 2.314 billion for the first nine months of 2025 [14]. - The maximum repurchase amount of RMB 80 million represents 1.64% of total assets, 3.82% of net assets, and 3.46% of revenue [14]. - The company asserts that the repurchase will not significantly impact its operations, financial status, or future development [14]. Shareholder and Management Plans - As of November 4, 2025, major shareholders and management have no plans to reduce their holdings in the next three to six months [3][16]. - The company will disclose any future shareholding changes in accordance with legal requirements [3][16]. Authorization and Implementation - The board has authorized management to execute the repurchase plan within legal limits, including adjustments based on market conditions [18][19]. - The company will maintain transparency and comply with disclosure obligations throughout the repurchase process [21].

Disclosure of trading in own shares occurred from November 3 to November 7, 2025 Saint-Cloud, November 10, 2025 In accordance with the regulations on share buybacks, in particular Regulation (EU) 2016/1052, Elis hereby declares the purchases of its own shares made from November 3 to November 7, 2025 under the buyback program authorized by the 24th resolution of the General Shareholders' Meeting of May 22, 2025 and announced on March 6, 2025: Aggregated presentation: Issuer nameIssuer code(LEI) Transaction d ...

Core Viewpoint - The company has repurchased a total of 1.775 million H shares at a cost of approximately HKD 29.176 million, aiming to enhance shareholder value and support its strategic goals in the medical imaging industry [1] Summary by Relevant Sections - **Share Buyback Details** - The company repurchased 1.775 million H shares over the past six months [1] - The total purchase price, excluding commissions and other expenses, was about HKD 29.176 million [1] - **Purpose of Share Buyback** - The repurchased shares will be held as treasury shares for employee incentives, sale, or transfer [1] - The board believes that the buyback will enhance share value, benefiting shareholders [1] - **Company's Strategic Outlook** - The company is committed to providing diversified imaging services and value across the entire medical imaging industry chain [1] - The board maintains a positive outlook on the company's future development prospects [1]

Core Viewpoint - The company has repurchased a total of 1.775 million H shares in the past six months, with a total expenditure of approximately HKD 29.176 million, excluding commissions and other expenses, to enhance shareholder value and support its strategic goals in the medical imaging industry [1] Summary by Relevant Sections - **Share Buyback Details** - The company repurchased 1.775 million H shares from the market [1] - The total cost of the buyback was approximately HKD 29.176 million [1] - **Purpose of Share Buyback** - The repurchased shares will be held as treasury shares for employee incentives, sale, or transfer [1] - The board believes that the buyback will enhance share value and benefit shareholders [1] - **Company's Strategic Outlook** - The company is committed to providing diversified imaging services and value across the entire medical imaging industry chain [1] - The board maintains a positive outlook on the company's future development prospects [1]

Group 1 - The company, Yipai Yangguang (02522.HK), announced the repurchase of a total of 1.775 million H-shares in the market over the past six months [1] - The total purchase price for the repurchased shares, excluding commissions and other expenses, was approximately HKD 29.18 million [1] - The repurchased shares will be held as treasury shares and are intended for employee incentives, sale, or transfer [1]

Core Points - China Petroleum & Chemical Corporation (Sinopec) has been actively repurchasing its shares, with a total of 4.072 million shares bought back on November 10 at prices ranging from 4.300 to 4.400 HKD, amounting to 17.7963 million HKD [1] - The stock has seen a cumulative increase of 4.03% during the recent buyback period starting from October 30, with a total of 30.396 million shares repurchased for a total of 128 million HKD [1] - Year-to-date, Sinopec has conducted 33 buybacks, repurchasing a total of 223 million shares for a total expenditure of 1.025 billion HKD [1] Buyback Details - On November 10, 2025, Sinopec repurchased 407.20 thousand shares at a maximum price of 4.400 HKD and a minimum price of 4.300 HKD, totaling 17.7963 million HKD [1] - The company has consistently repurchased shares over the past eight days, with the highest buyback occurring on August 22, 2025, where 6.762 million shares were repurchased at a maximum price of 4.430 HKD, totaling 297.7214 million HKD [1] - The buyback activity reflects a strategic move by Sinopec to enhance shareholder value amidst market fluctuations [1]

Core Viewpoint - The company believes its current stock price significantly undervalues its intrinsic value and future growth prospects [1] Summary by Sections - **Stock Buyback Announcement** - The company has repurchased a total of 549,800 ordinary shares as treasury stock from November 6, 2025, to the date of the announcement [1] - The repurchased shares represent approximately 0.24% of the company's total issued shares as of the announcement date [1] - The total amount involved in the buyback is approximately HKD 11.07 million, excluding commissions and other expenses [1]

| 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.11.10 | 39.20 | 15.960 | 15.830 | 624.30 | | 2025.11.07 | 40.00 | 15.920 | 15.750 | 632.76 | | 2025.11.06 | 40.00 | 15.990 | 15.860 | 637.01 | | 2025.11.05 | 6.64 | 15.500 | 15.420 | 102.73 | | 2025.09.26 | 100.00 | 16.120 | 15.830 | 1596.49 | | 2025.09.25 | 100.00 | 15.850 | 15.610 | 1574.99 | | 2025.09.22 | 120.00 | 16.260 | 16.030 | 1937.11 | | 2025.09.19 | 11.24 | 15.980 | 15.660 | 178.28 | | 2025.09.18 | 120.00 ...

Core Viewpoint - The company believes its current stock price significantly undervalues its intrinsic value and future growth prospects [1] Group 1: Share Buyback - The company has repurchased a total of 549,800 ordinary shares as treasury stock from November 6, 2025, to the date of the announcement [1] - The repurchased shares represent approximately 0.24% of the company's total issued shares as of the announcement date [1] - The total amount involved in the buyback is approximately HKD 11.07 million, excluding commissions and other expenses [1]